NCT04146051Active, not recruitingPhase 2
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 29 Oct 2019
- Start date
- 4 Dec 2019
- Primary completion date
- 5 Jan 2026
- Lead sponsor
- Cartesian Therapeutics
- Diseases
- Myasthenia gravis
- NCT number
- NCT04146051
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 4 Dec 2019 to the primary completion date, 5 Jan 2026
- 15 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
Other
- Patient is pregnant or lactating.
Who the study is looking for
- Patient must be at least 18 years of age.
- Patient must have Generalized Myasthenia Gravis at the time of screening.
- Concomitant immunosuppressive drugs must be deemed necessary by the investigator.
- Seronegative Patients are included
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alberta Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
| Dent Neurologic Institute Coordinator of this site? Confirm its status | Amherst | United States | Unknown status |
| University of Augusta Coordinator of this site? Confirm its status | Augusta | United States | Unknown status |
| University of Colorado Anschutz Medical Campus Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
| SFM Clinical Research LLC Coordinator of this site? Confirm its status | Boca Raton | United States | Unknown status |
| Profound Research Coordinator of this site? Confirm its status | Carlsbad | United States | Unknown status |
| University of North Carolina Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
| University of California, Irvine Coordinator of this site? Confirm its status | Irvine | United States | Unknown status |
| University of Kansas Medical Center Research Institute Coordinator of this site? Confirm its status | Kansas City | United States | Unknown status |
| Neurology Associates, P.A. Coordinator of this site? Confirm its status | Orlando | United States | Unknown status |
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| Allegheny Health Network Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
| Oregon Health Science University Coordinator of this site? Confirm its status | Portland | United States | Unknown status |
| Virginia Commonwealth University Coordinator of this site? Confirm its status | Richmond | United States | Unknown status |
| University of South Florida Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
Related publications
- BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.Nat Med · 2026 · PMID 41514039
- BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.Nat Med · 2026 · PMID 41514038
This page is information, not medical advice. Discuss any trial with your doctor.